title: A critical review of HER2-positive gastric cancer evaluation and treatment: from trastuzumab, and beyond.
abstract: Identification of the importance of human epidermal growth factor receptor-2 (HER2) status, biomarker testing and the development of anti-HER2 treatments have changed the prognosis of breast and gastric cancers. The addition of trastuzumab to chemotherapy has improved outcomes for patients with HER2-positive metastatic adenocarcinoma of the stomach and gastroesophageal junction, but some relevant issues remain to be elucidated or will emerge with new drugs. This article reviews the current state of HER2 in gastric cancer focusing on diagnostic and anti-HER2 targeted treatment issues and the role of trastuzumab in localized disease, and its combination or integration with new therapies.
authors.affiliation: Gastrointestinal Cancer Unit and Early Drug Development Unit, Medical Oncology Division, "12 de Octubre" University Hospital, Madrid, Spain; Laboratorio de Dianas Terapéuticas, Centro Integral Oncológico Clara Campal, Hospital Universitario Madrid Sanchinarro, Facultad de Medicina, Universidad San Pablo CEU, Madrid, Spain. Electronic address: cgomezmartin@salud.madrid.org.
authors.forename: Carlos
authors.initials: C
authors.lastname: Gomez-Martín
authors.affiliation: Laboratorio de Dianas Terapéuticas, Centro Integral Oncológico Clara Campal, Hospital Universitario Madrid Sanchinarro, Facultad de Medicina, Universidad San Pablo CEU, Madrid, Spain.
authors.forename: Fernando
authors.initials: F
authors.lastname: Lopez-Rios
authors.affiliation: Medical Oncology Department, Hospital Universitari i Politècnic La Fe, Valencia, Spain.
authors.forename: Jorge
authors.initials: J
authors.lastname: Aparicio
authors.affiliation: Upper GI Unit, Oncology Department, La Paz University Hospital-IdIPAZ, Madrid, Spain.
authors.forename: Jorge
authors.initials: J
authors.lastname: Barriuso
authors.affiliation: Medical Oncology Department, Hospital Universitario Virgen del Rocío, Instituto de Biomedicina de Sevilla (IBIS), Universidad de Sevilla, CSIC, HUVR, Sevilla, Spain.
authors.forename: Rocio
authors.initials: R
authors.lastname: García-Carbonero
authors.affiliation: Medical Oncology Department, Hospital Universitario Miguel Servet, Zaragoza, Spain.
authors.forename: Roberto
authors.initials: R
authors.lastname: Pazo
authors.affiliation: Medical Oncology Department, University Hospital Marqués de Valdecilla, Santander, Spain.
authors.forename: Fernando
authors.initials: F
authors.lastname: Rivera
authors.affiliation: Medical Oncology Department, Complejo Hospitalario de Ourense, Ourense, Spain.
authors.forename: Mercedes
authors.initials: M
authors.lastname: Salgado
authors.affiliation: Medical Oncology Department, Hospital Universitario Arnau de Vilanova de Lleida, Lleida, Spain.
authors.forename: Antonieta
authors.initials: A
authors.lastname: Salud
authors.affiliation: Gastroenterology Department, Hospital Ramón y Cajal, Madrid, Spain.
authors.forename: Enrique
authors.initials: E
authors.lastname: Vázquez-Sequeiros
authors.affiliation: University Cancer Center Leipzig, University Clinic Leipzig, Germany.
authors.forename: Florian
authors.initials: F
authors.lastname: Lordick
mesh_terms: D000230:Adenocarcinoma / Q000188:drug therapy / Q000378:metabolism* / Q000556:secondary; D000818:Animals; D061067:Antibodies, Monoclonal, Humanized / Q000627:therapeutic use*; D000970:Antineoplastic Agents / Q000627:therapeutic use*; D014408:Biomarkers, Tumor / Q000378:metabolism; D002986:Clinical Trials as Topic; D006801:Humans; D011379:Prognosis; D018719:Erb-b2 Receptor Tyrosine Kinases / Q000378:metabolism*; D013274:Stomach Neoplasms / Q000188:drug therapy / Q000378:metabolism* / Q000473:pathology; D000068878:Trastuzumab
chemical_list: D061067:Antibodies, Monoclonal, Humanized; D000970:Antineoplastic Agents; D014408:Biomarkers, Tumor; D018719:Erb-b2 Receptor Tyrosine Kinases; D000068878:Trastuzumab; C508053:ERBB2 protein, human
keywords: Gastric cancer; HER2; Review; Trastuzumab